Novel Glycoprotein VI Antagonists as Antithrombotics: Synthesis, Biological Evaluation, and Molecular Modeling Studies on 2,3-Disubstituted Tetrahydropyrido(3,4-<i>b</i>)indoles
作者:Shome S. Bhunia、Ankita Misra、Imran A. Khan、Stuti Gaur、Manish Jain、Surendra Singh、Aaruni Saxena、Thomas Hohlfield、Madhu Dikshit、Anil K. Saxena
DOI:10.1021/acs.jmedchem.6b01360
日期:2017.1.12
The development of small molecule inhibitors targeting GPVI has promising therapeutic role, as they inhibit arterial thrombosis with limited risk of bleeding. Among the compounds showing in vivo antithrombotic activity, the most active compound 6b (ED50 = 28.36 μmol/kg po in mice) showed improved inhibition for collagen (IC50 = 6.7 μM), CRP-XL (IC50 = 53.5 μM), and convulxin (CVX) (IC50 = 5.7 μM) mediated
靶向GPVI的小分子抑制剂的开发具有广阔的治疗作用,因为它们可抑制动脉血栓形成并具有有限的出血风险。在显示体内抗血栓形成活性的化合物中,活性最高的化合物6b(小鼠体内的ED 50 = 28.36μmol/ kg po)显示出对胶原蛋白(IC 50 = 6.7μM),CRP-XL(IC 50 = 53.5μM)的抑制作用,与氯沙坦(LOS)(胶原蛋白,IC 50 = 10.4μM; CRP-XL,IC 50 = 158μM; CVX,IC 50 = 11μM)相比,惊厥毒素(CVX)(IC 50 = 5.7μM )介导的血小板凝集任何其对映异构体S(6c)(胶原蛋白,IC50 = 25.3μM;CRP-XL,IC 50 = 181.4μM;CVX,IC 50 = 9μM)和R(6d)(胶原,IC 50 = 126.3μM; CRP-XL,IC 50 > 500μM; CVX,IC 50 = 86